Advertisement
CorrigendumNeuroscience Free access | 10.1172/JCI30951C1
Find articles by Dai, Y. in: JCI | PubMed | Google Scholar
Find articles by Wang, S. in: JCI | PubMed | Google Scholar
Find articles by Tominaga, M. in: JCI | PubMed | Google Scholar
Find articles by Yamamoto, S. in: JCI | PubMed | Google Scholar
Find articles by Fukuoka, T. in: JCI | PubMed | Google Scholar
Find articles by Higashi, T. in: JCI | PubMed | Google Scholar
Find articles by Kobayashi, K. in: JCI | PubMed | Google Scholar
Find articles by Obata, K. in: JCI | PubMed | Google Scholar
Find articles by Yamanaka, H. in: JCI | PubMed | Google Scholar
Find articles by Noguchi, K. in: JCI | PubMed | Google Scholar
Published October 1, 2007 - More info
Proinflammatory agents trypsin and mast cell tryptase cleave and activate PAR2, which is expressed on sensory nerves to cause neurogenic inflammation. Transient receptor potential A1 (TRPA1) is an excitatory ion channel on primary sensory nerves of pain pathway. Here, we show that a functional interaction of PAR2 and TRPA1 in dorsal root ganglion (DRG) neurons could contribute to the sensation of inflammatory pain. Frequent colocalization of TRPA1 with PAR2 was found in rat DRG neurons. PAR2 activation increased the TRPA1 currents evoked by its agonists in HEK293 cells transfected with TRPA1, as well as DRG neurons. Application of phospholipase C (PLC) inhibitors or phosphatidylinositol-4,5-bisphosphate (PIP2) suppressed this potentiation. Decrease of plasma membrane PIP2 levels through antibody sequestration or PLC-mediated hydrolysis mimicked the potentiating effects of PAR2 activation at the cellular level. Thus, the increased TRPA1 sensitivity may have been due to activation of PLC, which releases the inhibition of TRPA1 from plasma membrane PIP2. These results identify for the first time to our knowledge a sensitization mechanism of TRPA1 and a novel mechanism through which trypsin or tryptase released in response to tissue inflammation might trigger the sensation of pain by TRPA1 activation.
Yi Dai, Shenglan Wang, Makoto Tominaga, Satoshi Yamamoto, Tetsuo Fukuoka, Tomohiro Higashi, Kimiko Kobayashi, Koichi Obata, Hiroki Yamanaka, Koichi Noguchi
Original citation: J. Clin. Invest.117:1979-1987 (2007). doi:10.1172/JCI30951.
Citation for this corrigendum: J. Clin. Invest.117:3140 (2007). doi:10.1172/JCI30951C1.
During the preparation of the manuscript, the doses of ET-18-OCH3, U73122, and GF were incorrectly reported in the legend for Figure 3. The correct sentence appears below.
In some experiments, the bath solution was perfused with either a PLC inhibitor - ET-18-OCH3 (ET; 2 mM) or U73122 (2 mM) - or a PKC inhibitor, GF (0.5 mM or 10 mM) 120 seconds before SL-NH2 reapplication.
The authors regret the error.